Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 2/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22430427 | 0.77 | ALDH1A1 (0.32) | ALDH1A1HSD17B10KIF11CYP3A4CYP2D6 | |
| SCHEMBL761991 | 0.76 | ALDH1A1 (0.41) | ALDH1A1HSD17B10PKLRTRPV1KIF11 | |
| SCHEMBL15465950 | 0.73 | ALDH1A1 (0.41) | ALDH1A1HSD17B10PKLRTRPV1 | |
| SCHEMBL475888 | 0.67 | KIF11 (0.42) | KIF11CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3224144 | 0.66 | ALDH1A1 (0.41) | ALDH1A1HSD17B10NAMPT | |
| SCHEMBL5802691 | 0.66 | KCNA5 (0.34) | ALDH1A1HSD17B10PKLRTRPV1 | |
| SCHEMBL19326981 | 0.66 | ALDH1A1 (0.37) | ALDH1A1HSD17B10PKLRTRPV1NAMPT | |
| Hydrazine SCHEMBL5242106 | 0.64 | ALDH1A1 (0.47) | ALDH1A1HSD17B10 | |
| Hydrazine SCHEMBL27575629 | 0.64 | SMN1; SMN2 (0.47) | ALDH1A1HSD17B10PKLR | |
| SCHEMBL288904 | 0.63 | ALDH1A1 (0.46) | ALDH1A1HSD17B10TRPV1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | ALDH1A1 896/4885HSD17B10 798/4885PKLR 2902/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | ALDH1A1 896/4885HSD17B10 798/4885PKLR 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.